Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking
Abstract
PURPOSE: To determine whether (1) tailored nicotine patch therapy that is based on smoking rate can be carried out in a multisite oncology investigative group practice setting, (2) long-term use of bupropion reduces the rate of relapse to smoking in smokers who stop smoking with nicotine patch therapy, and (3) bupropion can initiate smoking abstinence among smokers who have failed to stop smoking after nicotine patch therapy. PARTICIPANTS AND METHODS: Fourteen North Central Cancer Treatment Group sites recruited generally healthy adult smokers from the general population for nicotine patch therapy and based the patch dosage on smoking rates. At completion of nicotine patch therapy, nonsmoking participants were eligible to be assigned to bupropion or placebo for 6 months (for relapse prevention). and smoking participants were eligible to be assigned to bupropion or placebo for 8 weeks of treatment. RESULTS: Of 578 subjects, 31% were abstinent from smoking at the end of nicotine patch therapy. Of those subjects not smoking at the end of nicotine patch therapy who entered the relapse prevention phase, 28% and 25% were not smoking at 6 months (the end of the medication phase) for bupropion and placebo, respectively (P =.73). For those still smoking at the end of nicotine patch therapy, 3.1% and 0.0% stopped smoking with bupropion or placebo, respectively (P =.12). CONCLUSION: Tailored nicotine patch therapy for the general population of smokers can be provided in a multisite oncology investigative group setting. Bupropion did not reduce relapse to smoking in smokers who stopped smoking with nicotine patch therapy. Bupropion did not initiate abstinence among smokers who failed to stop smoking with nicotine patch therapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bupropion did not sustain long-term abstinence post-medication (OR 1.2, 95% CI 0.8 to 1.7).
“however this and another study (115) did not show that bupropion would sustain long term abstinence post-medication (OR 1.2, 95% CI 0.8, 1.7; 116).”
From Tobacco addiction (2008) · cites this paper as [116]
Cites
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,406 · see citing works
(1992) · PubMed · Cited by 33,716 · see citing works
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033 · see citing works
(2005) · Springer eBooks · doi:10.1007/0-387-27255-0_9 · Cited by 20,333 · see citing works
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738 · see citing works
Hapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,406 · see citing works
Treating tobacco use and dependence-Clinical practice guideline
Mc, F. (2000) · Medical Entomology and Zoology · Cited by 3,616 · see citing works
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350 · see citing works
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · see citing works
A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation
Hurt, R. D., Sachs, D. P. L., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., Khayrallah, M. A., Schroeder, D. R., Glover, P. N., Sullivan, C. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710233371703 · Cited by 1,253 · see citing works
Recent Advances in the Pharmacotherapy of Smoking
Hughes, J. R. (1999) · JAMA · doi:10.1001/jama.281.1.72 · Cited by 380 · see citing works
Hays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P. L., Wolter, T. D., Buist, A. S., Johnston, J. A., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00011 · Cited by 343 · see citing works
Analyzing Data from Ordered Categories
Moses, L. E., Emerson, J. D., & Hosseini, H. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408163110705 · Cited by 316 · see citing works
Tonnesen (1999) · doi:10.1034/j.1399-3003.1999.13b04.x · Cited by 260 · see citing works
High-dose nicotine patch therapy. Percentage of replacement and smoking cessation
Dale, L. C. (1995) · JAMA · doi:10.1001/jama.274.17.1353 · Cited by 251 · see citing works
Varying Nicotine Patch Dose and Type of Smoking Cessation Counseling
Jorenby, D. E. (1995) · JAMA · doi:10.1001/jama.1995.03530170027027 · Cited by 232 · see citing works
Nicotine Patch Therapy for Smoking Cessation Combined With Physician Advice and Nurse Follow-up
Hurt, R. D. (1994) · JAMA · doi:10.1001/jama.1994.03510320035026 · Cited by 209 · see citing works
Are higher doses of nicotine replacement more effective for smoking cessation?
Hughes, J. R., Lesmes, G. R., Hatsukami, D. K., RICHMOND, R. L., Lichtenstein, E. H., Jorenby, D. E., Broughton, J. O., Fortmann, S. P., Leischow, S. J., McKenna, J., et al. (1999) · Nicotine & Tobacco Research · doi:10.1080/14622299050011281 · Cited by 143 · see citing works
The Use of a Self-Administered Alcoholism Screening Test (SAAST) in a Medical Center
Swenson, W. M., & Morse, R. M. (1975) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)09652-1 · Cited by 119 · see citing works
Dose-related cardiovascular and endocrine effects of transdermal nicotine*
Zevin, S., Jacob, P., & Benowitz, N. L. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90026-1 · Cited by 89 · see citing works
Fredrickson, P. A., Lee, G. M., Wingender, L., Hurt, R. D., Croghan, I. T., Lauger, G., Offord, K. P., & Gomez‐Dahl, L. C. (1995) · Psychopharmacology · doi:10.1007/bf02246542 · Cited by 65 · see citing works
Do heavy smokers benefit from higher dose nicotine patch therapy?
Killen, J. D., Fortmann, S. P., Davis, L., Strausberg, L., & Varady, A. N. (1999) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.7.3.226 · Cited by 62 · see citing works
Croghan, G. A., Sloan, J. A., Croghan, I. T., Novotny, P., Hurt, R. D., DeKrey, W. L., Walsh, D. J., Mailliard, J. A., Ebbert, L. P., Swan, D., et al. (2003) · Nicotine & Tobacco Research · doi:10.1080/1462220031000073252 · Cited by 60 · see citing works
Do heavy smokers benefit from higher dose nicotine patch therapy?
Killen, J. D., Fortmann, S. P., Davis, L., et al. (1999) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.7.3.226 · Cited by 49 · see citing works
Recycling with nicotine patches in smoking cessation
TØNNESEN, P., NØRREGAARD, J., SÄWE, U., & SIMONSEN, K. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02060.x · Cited by 48 · see citing works
Treatment of Nicotine Dependence Is More Better?
Hughes, J. R. (1995) · JAMA · doi:10.1001/jama.1995.03530170070035 · Cited by 30 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann‐Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,514 · see citing works
Nicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972 · see citing works
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., & Lancaster, T. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub3 · Cited by 721 · see citing works
Nicotine replacement therapy versus control for smoking cessation
Hartmann-Boyce, J., Chepkin, S. C., Ye, W., Bullen, C., & Lancaster, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub5 · Cited by 697 · see citing works
Tonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660 · see citing works
“A recent Cochrane review(5) identified 2 studies of bupropion vs placebo that examined continued abstinence in smokers who had initially quit either with bupropion(12) or with the nicotine patch.(16) These trials did not detect a significant effect at 6 months(16) or at 1 year(12) after the end of treatment.”
BackgroundAntidepressants for smoking cessation
Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567 · see citing works
Relapse prevention interventions for smoking cessation
Hájek, P., Stead, L. F., West, R., Jarvis, M. J., Hartmann‐Boyce, J., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003999.pub4 · Cited by 471 · see citing works
Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies
Mills, E. J., Thorlund, K., Eapen, S., Wu, P., & Prochaska, J. J. (2013) · Circulation · doi:10.1161/circulationaha.113.003961 · Cited by 405 · see citing works
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352 · see citing works
Antidepressants for smoking cessation.
Hughes, J., Stead, L., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub4 · Cited by 317 · see citing works
Interventions for preventing weight gain after smoking cessation
Farley, A., Hájek, P., Lycett, D., & Aveyard, P. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006219.pub3 · Cited by 333 · see citing works
Scharf, D. M., & Shiffman, S. M. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00845.x · Cited by 255 · see citing works
A Randomized Placebo-Controlled Clinical Trial of 5 Smoking Cessation Pharmacotherapies
Piper, M. E., Smith, S. S., Schlam, T. R., Fiore, M. C., Jorenby, D. E., Fraser, D. L., & Baker, T. B. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.142 · Cited by 245 · see citing works
“Future research should examine relapse dynamics following the discontinuation of treatment; it would be important to know if treatment discontinuation was more consequential for some pharmacotherapies than for others.(27,28) Future research should also address the promising issue of using pharmacotherapy prior to the…”
BackgroundHatsukami, D. K., Stead, L. F., & Gupta, P. C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60871-5 · Cited by 227 · see citing works
Antidepressants for smoking cessation
Hughes, J., Stead, L., & Lancaster, T. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub2 · Cited by 172 · see citing works
The feasibility of smoking reduction: an update
Hughes, J. R., & Carpenter, M. J. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01174.x · Cited by 168 · see citing works
“…(Table 2), four of the trials tested a behavioral therapy (Lichtenstein & Rodrigues 1977;Lando & McGovern 1982;Glasgow et al. 1989;Becona & Garcia 1993) and six a medication (Fornai et al. 1996;Hughes et al. 1981;Norregaard et al. 1992;Hurt et al. 2003;Jolicoeur et al. 2003;Hughes et al. 2004b).”
BackgroundInfluentialThomas, K. H., Dalili, M. N., López-López, J. A., Keeney, E., Phillippo, D., Munafo, M. R., Stevenson, M., Caldwell, D. M., & Welton, N. J. (2021) · Health Technology Assessment · doi:10.3310/hta25590 · Cited by 153 · see citing works
Agboola, S., McNeill, A., Coleman, T., & Leonardi Bee, J. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.02996.x · Cited by 150 · see citing works
Extended treatment of older cigarette smokers
Hall, S. M., Humfleet, G. L., Muñoz, R. F., Reus, V. I., Robbins, J. A., & Prochaska, J. J. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02548.x · Cited by 125 · see citing works
“Abstinence rates did not differ between conditions [8].”
BackgroundThe prevalence of weight concerns in a smoking abstinence clinical trial
Clark, M. M., Hurt, R. D., Croghan, I. T., Patten, C. A., Novotny, P. J., Sloan, J. A., Dakhil, S. R., Croghan, G. A., Wos, E. J., Rowland, K. M., et al. (2005) · Addictive Behaviors · doi:10.1016/j.addbeh.2005.08.011 · Cited by 117 · see citing works
Prevention of Relapse After Quitting Smoking
Lancaster, T., Hájek, P., Stead, L. F., West, R., & Jarvis, M. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.8.828 · Cited by 102 · see citing works
“Four studies randomized abstainers to pharmacological interventions, including nicotine chewing gum(10,11) and bupropion hydrochloride.(34,35)”
BackgroundInterventions for preventing weight gain after smoking cessation
Hartmann‐Boyce, J., Theodoulou, A., Farley, A., Hájek, P., Lycett, D., Jones, L. L., Kudlek, L., Heath, L., Hajizadeh, A., Schenkels, M., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006219.pub4 · Cited by 96 · see citing works
Winhusen, T. M., Somoza, E. C., Brigham, G. S., Liu, D. S., Green, C. A., Covey, L. S., Croghan, I. T., Adler, L. A., Weiss, R. D., Leimberger, J. D., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05089gry · Cited by 90 · see citing works
(2009) · doi:10.1002/14651858.cd003999.pub3 · Cited by 119 · see citing works
Animal models and treatments for addiction and depression co-morbidity
Paterson, N. E., & Markou, A. (2007) · Neurotoxicity Research · doi:10.1007/bf03033479 · Cited by 84 · see citing works
“Similarly, the antidepressant bupropion exerts its beneficial effects during the early phase of nicotine abstinence, when withdrawal symptoms are most severe (Hurt et al., 2003; Piasecki et al., 2003).”
BackgroundPaterson, N. E., Balfour, D. J. K., & Markou, A. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05546.x · Cited by 80 · see citing works
“Bupropion may also decrease relapse over more extended periods, such as 12 or 24 months of abstinence; nevertheless, data are inconclusive regarding the efficacy of bupropion during such long abstinence periods (Hays et al., 2001; Hurt et al., 2003; Killen et al., 2006).”
BackgroundExtended treatment with bupropion SR for cigarette smoking cessation
Killen, J. D., Fortmann, S. P., Murphy, G. M., Hayward, C., Arredondo, C., Cromp, D., Celio, M., Abe, L., Wang, Y., & Schatzberg, A. F. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.74.2.286 · Cited by 80 · see citing works
Extended cognitive behavior therapy for cigarette smoking cessation
Killen, J. D., Fortmann, S. P., Schatzberg, A. F., Arredondo, C., Murphy, G. M., Hayward, C., Celio, M., Cromp, D., Fong, D., & Pandurangi, M. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02273.x · Cited by 80 · see citing works
“At the end of extended treatment, 28% and 25% were not smoking for bupropion and placebo, respectively [7].”
BackgroundRelapse prevention interventions for smoking cessation
Livingstone-Banks, J., Norris, E., Hartmann-Boyce, J., West, R., Jarvis, M., Chubb, E., & Hajek, P. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003999.pub6 · Cited by 77 · see citing works
Liu, X., Caggiula, A. R., Palmatier, M. I., Donny, E. C., & Sved, A. F. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0967-9 · Cited by 77 · see citing works
“…activation in anterior cingulate cortex (Brody et al. 2004), smoking abstinence rates at 1 year with bupropion treatment remain at only 22–33% (Hurt et al. 1997; Jorenby et al. 1999; Hurt et al. 2003; Killen et al. 2006) and 35% when combined with nicotine replacement therapy (Jorenby et al. 1999).”
BackgroundInfluentialMills, E. J., Wu, P., Spurden, D., Ebbert, J. O., & Wilson, K. R. (2009) · Harm Reduction Journal · doi:10.1186/1477-7517-6-25 · Cited by 67 · see citing works
“Almost all trials (40/42) used a placebo control.[113,114,149,151-187], with 2 providing education.”
BackgroundMethodInfluentialRelapse prevention interventions for smoking cessation
Hájek, P., Stead, L., West, R., Jarvis, M. J., & Lancaster, T. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003999.pub2 · Cited by 66 · see citing works
Winhusen, T. M., Brigham, G. S., Kropp, F. B., Lindblad, R., Gardin, J. G., Penn, P., Hodgkins, C. C., Kelly, T. M., Douaihy, A. B., McCann, M., et al. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08449 · Cited by 64 · see citing works
Using Extended Cognitive Behavioral Treatment and Medication to Treat Dependent Smokers
Hall, S. M., Humfleet, G. L., Muñoz, R. F., Reus, V. I., Prochaska, J. J., & Robbins, J. A. (2011) · American Journal of Public Health · doi:10.2105/ajph.2010.300084 · Cited by 63 · see citing works
“Participants were then randomly assigned to 1 of 5 conditions: (1) no further treatment, (2) active bupropion SR for 40 weeks, (3) placebo for 40 weeks, (4) active bupropion SR and 11 sessions of CBT for 40 weeks (A-CBT), or (5) placebo and 11 sessions of CBT for 40 weeks.”
BackgroundMethodBupropion for the treatment of nicotine withdrawal and craving
Mooney, M. E., & Sofuoglu, M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.7.965 · Cited by 63 · see citing works
Nicotinic receptor-based therapeutics and candidates for smoking cessation
Dwoskin, L. P., Smith, A. M., Wooters, T. E., Zhang, Z., Crooks, P. A., & Bardo, M. T. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.06.002 · Cited by 56 · see citing works
Croghan, I. T., Hurt, R. D., Dakhil, S. R., Croghan, G. A., Sloan, J. A., Novotny, P. J., Rowland, K. M., Bernath, A., Loots, M. L., Le-Lindqwister, N. A., et al. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60997-x · Cited by 74 · see citing works
Nicotinic Receptor Antagonists as Treatments for Nicotine Abuse
Crooks, P. A., Bardo, M. T., & Dwoskin, L. P. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00013-5 · Cited by 54 · see citing works
“…relapse within the first month, and only 3% remain abstinent at 6 months (Benowitz, 2009), indicating that new medications are needed to specifically address the problem of relapse (George & O’Malley, 2004; Harmey, Griffin, & Kenny, 2012; Hurt et al., 2003; Irvin, Hendricks, & Brandon, 2003).”
Adapting Smoking Cessation Treatment According to Initial Response to Precessation Nicotine Patch
Rose, J. E., & Behm, F. M. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12070919 · Cited by 51 · see citing works
“Nonetheless, this finding is similar to other negative results from studies attempting to provide alternative treatments after relapse to smoking (19).”
ResultRohsenow, D. J., Monti, P. M., Hutchison, K. E., Swift, R. M., MacKinnon, S. V., Sirota, A. D., & Kaplan, G. B. (2007) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.15.1.81 · Cited by 50 · see citing works
“Procedures were based on those described in Hutchison et al. (1999) and Sayette and Hufford (1994).”
BackgroundMethodAntidepressants for smoking cessation
Hajizadeh, A., Howes, S., Theodoulou, A., Klemperer, E., Hartmann-Boyce, J., Livingstone-Banks, J., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub6 · Cited by 84 · see citing works
Covey, L. S., Glassman, A. H., Jiang, H., Fried, J., Masmela, J. R., LoDuca, C., Petkova, E., & Rodriguez, K. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01887.x · Cited by 48 · see citing works
Non-nicotine pharmacotherapies for smoking cessation
McRobbie, H. J., Lee, M.-S., & Juniper, Z. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2005.05.016 · Cited by 48 · see citing works
Winhusen, T. M., Kropp, F. B., Theobald, J., & Lewis, D. F. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.09.019 · Cited by 43 · see citing works
“PPA is a standard measure and is defined as self-report of not smoking in the previous seven days, confirmed by a CO level 8 ppm (Hurt et al., 2003).”
BackgroundRelapse prevention interventions for smoking cessation
Livingstone-Banks, J., Norris, E., Hartmann-Boyce, J., West, R., Jarvis, M., & Hajek, P. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003999.pub5 · Cited by 94 · see citing works
NIAURA, R. S., Chander, G., Hutton, H. E., & Stanton, C. A. (2012) · Current HIV/AIDS Reports · doi:10.1007/s11904-012-0138-4 · Cited by 39 · see citing works
Smoking Cessation Interventions in Clinical Practice
Cornuz, J. (2007) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2007.06.009 · Cited by 38 · see citing works
Paterson, N. E. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.12.009 · Cited by 36 · see citing works
Bupropion for Smoking Cessation: A Review
Tong, E. K., Carmody, T. P., & Simon, J. A. (2006) · Comprehensive Therapy · doi:10.1385/comp:32:1:26 · Cited by 33 · see citing works
Nicotine Replacement Therapy for Smoking Cessation
Takagi, K., Kato, N., Sasamoto, S., & Hata, Y. (2005) · Nihon Kikan Shokudoka Gakkai Kaiho · doi:10.2468/jbes.56.424 · Cited by 33 · see citing works
Hays, J. T., Hurt, R. D., Decker, P. A., Croghan, I. T., Offord, K. P., & Patten, C. A. (2009) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntp077 · Cited by 30 · see citing works
“…a previous study of bupropion SR used for smoking relapse prevention ( Hays et al., 2001 ) but are consistent with a study of tailored NRT followed by bupropion for smoking relapse prevention in a multicenter trial, both conducted among general population samples of smokers ( Hurt et al., 2003 ).”
MethodSong, F., Huttunen‐Lenz, M., & Holland, R. (2009) · Journal of Public Health · doi:10.1093/pubmed/fdp109 · Cited by 26 · see citing works
Extended treatment for cigarette smoking cessation: a randomized control trial
Laude, J. R., Bailey, S. R., Crew, E., Varady, A. N., Lembke, A., McFall, D., Jeon, A., Killen, D. T., Killen, J. D., & David, S. P. (2017) · Addiction · doi:10.1111/add.13806 · Cited by 26 · see citing works
“NRT (6-9), bupropion (10-14), nortriptyline (15) and varenicline (16) have been examined with extended treatment protocols (16).”
Combination Treatment for Nicotine Dependence: State of the Science
Ingersoll, K. S., & Cohen, J. X. (2005) · Substance Use & Misuse · doi:10.1080/10826080500294817 · Cited by 22 · see citing works
Pivavarchyk, M., Smith, A. M., Zhang, Z., Zhou, D., Wang, X., Toyooka, N., Tsuneki, H., Sasaoka, T., McIntosh, J. M., Crooks, P. A., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.02.018 · Cited by 21 · see citing works
“INTRODUCTION Several tobacco smoking cessation pharmacotherapies are available currently, but are limited by efficacy and high relapse rates (Hurt et al., 2003; George and O'Malley, 2004; Wileyto et al., 2004).”
Winhusen, T. M., Adinoff, B. H., Lewis, D. F., Brigham, G. S., Gardin, J. G., Sonne, S. C., Theobald, J., & Ghitza, U. E. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.09.002 · Cited by 20 · see citing works
“Finally, the present trial utilized a standard definition of smoking abstinence, which was self-report of not smoking in the previous seven days confirmed by a CO level <8 ppm (Hurt et al., 2003), but there is research to suggest that a CO level of 8–10 ppm may occasionally result in smokers falsely being classified a…”
BackgroundMethodSmoking Cessation 1: Pharmacological Treatments
Cofta-Woerpel, L. M., Wright, K. L., & Wetter, D. W. (2006) · Behavioral Medicine · doi:10.3200/bmed.32.2.47-56 · Cited by 19 · see citing works
Doggrell, S. A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.17.2903 · Cited by 16 · see citing works
“In subjects who have failed or succeeded in stopping smoking with nicotine patches, bupropion is unlikely to be effective or increase the success rates [71] .”
BackgroundInfluentialWinhusen, T. M., Stitzer, M. L., WOODY, G. E., Brigham, G. S., Kropp, F. B., Ghitza, U. E., Lindblad, R., Adinoff, B. H., Green, C. L., Sharma, G., et al. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.09.018 · Cited by 16 · see citing works
“Point-prevalence abstinence, defined as self-report of not smoking in the previous seven days, confirmed by a carbon monoxide (CO) level <8 ppm [40], is assessed weekly.”
BackgroundDoes bupropion have advantages over other medical therapies in the cessation of smoking?
Tonstad, S., & Johnston, J. A. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.4.727 · Cited by 14 · see citing works
“In a subsequent trial, 66% of 578 smokers treated with transdermal NRT for 8 weeks were randomised to bupropion SR or to placebo and followed for another 6 months [28].”
BackgroundMethodInfluentialTratamento farmacológico do tabagismo
Focchi, G. R. D. A., & Braun, I. M. (2005) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832005000500003 · Cited by 13 · see citing works
Mayer, C., Vandecasteele, H., Bodo, M., Primo, C., Slachmuylder, J., Kaufman, L., & Razavi, D. (2010) · The Journal of Smoking Cessation · doi:10.1375/jsc.5.1.83 · Cited by 12 · see citing works
Tobacco dependence counseling in a randomized multisite clinical trial
Croghan, I., Trautman, J. A., Winhusen, T. M., Ebbert, J., Kropp, F. B., Schroeder, D., & Hurt, R. (2012) · Contemporary Clinical Trials · doi:10.1016/j.cct.2012.02.014 · Cited by 12 · see citing works
“We chose to use this manual because of its past success [10-20] in helping smokers through their tobacco dependence treatment.”
MethodTrials that Matter: Varenicline: A Designer Drug to Help Smokers Quit
Schroeder, S. A., & Sox, H. C. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00013 · Cited by 12 · see citing works
Dwoskin, L. P., Pivavarchyk, M., Joyce, B. M., Neugebauer, N. M., Zheng, G., Zhang, Z., Bardo, M. T., & Crooks, P. A. (2008) · Nebraska Symposium on Motivation/The Nebraska symposium on motivation · doi:10.1007/978-0-387-78748-0_4 · Cited by 11 · see citing works
Hotta, K., Kinumi, K., Naito, K., Kuroki, K., Sakane, H., Imai, A., Kobayashi, M., Ohnishi, M., Ogura, T., Miura, H., et al. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01466.x · Cited by 11 · see citing works
Pharmacologic Interventions for Smoking Cessation
Corelli, R. L., & Hudmon, K. S. (2006) · Critical Care Nursing Clinics of North America · doi:10.1016/j.ccell.2005.11.006 · Cited by 11 · see citing works
“Studies using transdermal nicotine in doses up to 44 to 63 mg/d suggest that high-dose NRT is safe [34–37], but trials evaluating the effectiveness of high-dose NRT have yielded conflicting results.”
BackgroundDwoskin, L. P., Joyce, B. M., Zheng, G., Neugebauer, N. M., Manda, V. K., Lockman, P. R., Papke, R. L., Bardo, M. T., & Crooks, P. A. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.021 · Cited by 10 · see citing works
“…University of Kentucky, Lexington, KY 40536-0082, United States cDepartment of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, School of Pharmacy, Amarillo, TX 79106, United States dDepartment of Pharmacology and Therapeutics, College of Medicine, University of Florida,…”
BackgroundSumithran, S. P., Crooks, P. A., Xu, R., Zhu, J., Deaciuc, A. G., Wilkins, L. H., & Dwoskin, L. P. (2005) · The AAPS Journal · doi:10.1208/aapsj070119 · Cited by 9 · see citing works
Treating tobacco use and dependence in clinical practice
Cornuz, J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.6.783 · Cited by 8 · see citing works
“In a study that tested the use of bupropion for retreating smokers who had just failed to quit with NRT, only one participant (from the bupropion treatment arm) was abstinent after 6 months [27].”
BackgroundHendricks, P. S., Hall, S. M., Tyus, L. R., Thorne, C. B., Lappan, S. N., McMurray, M., Bailey, W. C., Cropsey, K. L., & Baker, T. B. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.04.022 · Cited by 8 · see citing works
Tobacco Cessation: New Challenges, New Opportunities
Hopper, J. A., & Gallagher, R. (2003) · Journal of Cancer Education · doi:10.1207/s15430154jce1803_05 · Cited by 7 · see citing works
Treatment Options in Smoking Cessation: What Place for Bupropion Sustained-Release?
McCarthy, D. E., Jorenby, D. E., Minami, H., & Yeh, V. M. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2044 · Cited by 5 · see citing works
A Brief Review of Pharmacotherapies for Smoking Cessation
Lam, C. Y., Minnix, J. A., Robinson, J. D., & Cinciripini, P. M. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.0047 · Cited by 4 · see citing works
Chandler, M. A., & Rennard, S. I. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374001-4.00047-x · Cited by 1 · see citing works
Tratamiento farmacológico del tabaquismo
Martín, F., & Corral, L. P. (2004) · Trastornos Adictivos · doi:10.1016/s1575-0973(04)70151-8 · Cited by 1 · see citing works
Smoking cessation in patients with chronic obstructive pulmonary disease and lung cancer
Jimenez-Ruiz, C. A. (2008) · Hot Topics in Respiratory Medicine · doi:10.4147/htr-080815
Smoking cessation: evidence based practice
Ward, K. (2009) · Professional nursing today
Nützt die Tabak-Rezidiv-Prävention etwas?
von Garnier, C. (2010) · Therapeutische Umschau · doi:10.1024/0040-5930/a000076
Sustained- Release Bupropion as a Pharmacological Aid to Smoking Cessation
Hays, J. T., & Ebbert, J. O. (2006) · CRC Press eBooks · doi:10.1201/9781420005431.ch5
Maggio, S. E. (2019) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2019.395
(2017) · Dunod eBooks · doi:10.3917/dunod.guich.2017.01.0161
Medikamentöse Behandlung des Rauchers
Haustein, K.-O. (2008) · Springer eBooks · doi:10.1007/978-3-540-73309-6_13
The MD Anderson Cancer Center Moon Shots Program®: A Global Priority
Papadopoulos, P. C., Roarty, E. B., Bello, R. S., Domgue, J. F., Shete, S. S., & Maitra, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-69584-8.00062-1
Health recommender systems for behavior change
Hors-Fraile, S. (2022) · doi:10.26481/dis.20220324sh
Recent publications by ochsner authors.
(2003) · PubMed Central
- Authors
- Hurt, R. D., Krook, J. E., Croghan, I. T., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Kardinal, C. G., Knost, J. A., Tirona, M. T., Addo, F., Morton, R. F., Michalak, J. C., Schaefer, P. L., Porter, P. A., & Stella, P. J.
- Affiliations
- Mayo Clinic (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2003-03-01
- Volume
- 21
- Issue
- 5
- Pages
- 914-920
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2153220298
- Cited by
- 86
- References
- 25
- Citations by year
- 2023: 1 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 2 · 2016: 1 · 2014: 2 · 2013: 6 · 2012: 4
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u10ca063826-02)
- National Cancer Institute (CA 35101, CA- 35113, CA35103, CA35195, U10CA035113, U10CA035103, CA 52352, CA35272, CA35448, U10CA035448, U10CA063848, (CA-25224, CA-35415, U10CA035272, CA-37404, U10CA035415, CA 63826, U10CA037404, U10CA025224, U10CA052352, U10CA035195, CA 15083, U10CA035101, P30CA015083, CA-63848)
- Topics
- Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Keywords
- bupropion, smoking cessation, relapse prevention, smoking prevalence, smoking abstinence, cancer patients
- MeSH terms
- Smoking Prevention, Adolescent, Adult, Aged, Aged, 80 and over, Delayed-Action Preparations, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Nicotine, Recurrence, Smoking, Smoking Cessation, Bupropion, Treatment Outcome, Dopamine Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
